ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of ...
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...
Clinical Trials Arena on MSN
Novocure’s Optune Gio fails to show benefit at earlier stage
The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
By Sneha S K June 18 (Reuters) - Novocure said on Thursday that a late-stage trial showed early use of its non-invasive cancer therapy did not significantly improve overall survival in patients with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...
A head patch device that delivers alternating electrical fields to the brain has been shown to significantly improve survival in newly diagnosed glioblastoma patients. Developed by Jersey, US-based ...
Novocure (NVCR +1.91%) has been on a tremendous run-- up 17 times over the last five years -- leaving many investors thinking that they missed the boat. But in investing, winners keep on winning.
NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients. Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform. NVCR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results